VIRI - Earnings announcements

ATLANTA, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the "Company"), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia ("FM") and Long-COVID ("LC"), announced today that it will report second quarter 2024 financial results on Thursday, August 8, 2024 before the open of the financial markets. About Virios Therapeutics Virios Therapeutics (NASDAQ:VIRI) is a development-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response such as fibromyalgia ("FM") and Long-CO

- Top-line results from the ongoing investigator-initiated Bateman Horne Center Long-COVID phase 2 featuring valacyclovir and celecoxib (IMC-2) expected in the second-half of 2024 - - Conference Call Today at 8:30 a.m. ET - ATLANTA, May 09, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (NASDAQ:VIRI) (the "Company"), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia ("FM") and Long-COVID ("LC"), today announced financial results for the first quarter ended March 31, 2024 and provided a corporate update. Key Highlights The BHC-202 3-arm study comparing two dose levels of the valacyc

ATLANTA, May 02, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the "Company"), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia ("FM") and Long-COVID ("LC"), announced today that it will report first quarter 2024 financial results on Thursday, May 9, 2024 before the open of the financial markets. Management will also host a webcast and conference call on May 9, 2024 at 8:30 a.m. ET to discuss the results and provide a corporate update. The live and archived webcast of the call may be accessed on the Virios Therapeutics website under the Investors section: Events and

- Conference Call Today at 8:30 a.m. ET - ATLANTA, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (NASDAQ:VIRI) (the "Company"), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia ("FM") and Long-COVID ("LC"), today announced financial results for the third quarter ended September 30, 2023. Key Highlights and Upcoming Milestones Having secured FDA guidance on our plan to progress IMC-1 to Phase 3 development to treat fibromyalgia (FM), we can convey that several life science companies are engaged and reviewing our Phase 2 data and proposed Phase 3 program as the basis for a

ATLANTA, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the "Company"), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia ("FM") and Long-COVID, announced today that it will report third quarter 2023 financial results on Monday, November 13, 2023 before the open of the financial markets. Management will also host a webcast and conference call on November 13, 2023 at 8:30 a.m. ET to discuss the results and provide a corporate update. The live and archived webcast of the call may be accessed on the Virios Therapeutics website under the Investors sec

- Continued Progress in Expanding and Advancing Clinical Pipeline -- Conference Call Today at 8:30 a.m. ET - ATLANTA, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (NASDAQ:VIRI) (the "Company"), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia ("FM") and Long-COVID, today announced financial results for the second quarter ended June 30, 2023 and provided a corporate update. Key Highlights and Upcoming Milestones The Company announced that the Food & Drug Administration ("FDA") communicated that, following their initial review of the Company's chronic toxicology program, t

ATLANTA, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the "Company"), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia ("FM") and Long-COVID, announced today that it will report second quarter 2023 financial results on Thursday, August 10, 2023 before the open of the financial markets. Management will also host a webcast and conference call on August 10, 2023 at 8:30 a.m. ET to discuss the results and provide a corporate update. The live and archived webcast of the call may be accessed on the Virios Therapeutics website under the Investors sect

ATLANTA, Ga., May 04, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the "Company"), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia ("FM"), today announced that it will report first quarter 2023 financial results on Thursday, May 11, 2023 before the open of the financial markets. About Virios Therapeutics Virios Therapeutics (NASDAQ:VIRI) is a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, such as fibromyalgia ("FM"). Immune responses related to the activation of tissue re

ATLANTA, March 07, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia ("FM"), announced today that it will report fourth quarter and full year 2022 financial results on Tuesday, March 14, 2023 before the open of the financial markets. Given the upcoming mid-March end-of-Phase 2 meeting with the U.S. Food and Drug Administration ("FDA") to discuss advancing IMC-1 into Phase 3 development as a treatment for FM, the Company plans to host its next webcast and conference call for the investment community in late April 2023 to pr

- FORTRESS Study Analysis Reveals Fibromyalgia Patients New to Research Demonstrate Significant IMC-1 Pain Reduction Treatment Benefits - - Company Believes FORTRESS Safety Data Supports Phase 3 Development, Requesting FDA Meeting to Discuss Next Steps - - Patient Dosing Continues in IMC-2 Exploratory Long-COVID Treatment Study - - Conference Call Today at 8:30 a.m. ET - Virios Therapeutics, Inc. (NASDAQ:VIRI) (the "Company"), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases including fibromyalgia ("FM"), today announced financial results for the third quarter ended September 30, 2022, as well as

Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, announced today that its third quarter 2022 financial results will be reported on Monday, November 14, 2022 before the open of the financial markets. Management will also host a webcast and conference call on November 14, 2022 at 8:30 a.m. ET to discuss the results and provide a corporate update. The live and archived webcast of the call may be accessed on the Virios Therapeutics website under the Investors section: Events and Presentations. The live call can also be accessed by dialin

Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia ("FM"), today announced topline results from its FORTRESS (Fibromyalgia Outcome Research Trial Evaluating Synergistic Suppression of Herpes Simplex Virus-1 ("HSV-1")) study of oral IMC-1 for the treatment of FM. Overall, the FORTRESS study did not achieve statistical significance on the prespecified primary efficacy endpoint of change from baseline to Week 14 in the weekly average of daily self-reported average pain severity scores comparing IMC-1 to placebo (p=0.302). However, analysis

- Top Line FORTRESS Study Data Expected in September 2022 - - Conference Call Today at 8:30 a.m. ET - Virios Therapeutics, Inc. (NASDAQ:VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases including fibromyalgia, today announced financial results for the second quarter ended June 30, 2022. Key Highlights and Upcoming Milestones Completed patient dosing in Phase 2b FORTRESS fibromyalgia study Top line FORTRESS results expected in September 2022 "Data published earlier this year provide evidence of a mechanistic correlation between activated herpes viruses and patients suffering from fibrom

Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, announced today that its second quarter 2022 financial results will be reported on Thursday, August 11, 2022 before the open of the financial markets. Management will also host a webcast and conference call on August 11, 2022 at 8:30 a.m. ET to discuss the results and provide a corporate update. The live and archived webcast of the call may be accessed on the Virios Therapeutics website under the Investors section: Events and Presentations. The live call can also be accessed by dialing

- Enrollment Completed in FORTRESS Study with Top Line Data Expected in September 2022 - - Conference Call Today at 8:30 a.m. ET - Virios Therapeutics, Inc. (NASDAQ:VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, today announced financial results for the first quarter ended March 31, 2022. Key Highlights Completed enrollment in Phase 2b FORTRESS fibromyalgia study with top line results expected in September 2022 Targeting completion of chronic toxicology studies concurrent with FORTRESS study results in preparation for fibromyalgia Phase 3 program Presented a

Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, announced today that its first quarter 2022 financial results will be reported on Thursday, May 12, 2022 before the open of the financial markets. Management will also host a webcast and conference call on May 12, 2022 at 8:30 a.m. ET to discuss the results and provide a corporate update. The live and archived webcast of the call may be accessed on the Virios Therapeutics website under the Investors section: Events and Presentations. The live call can also be accessed by dialing 888-50

- Top line Data from Phase 2b FORTRESS Study of IMC-1 on Track for Q3 2022 - - Pipeline Expanded with IMC-2 as Treatment for Long COVID to be Evaluated in New Exploratory Study Targeted to Commence in Q2 2022 - - Conference Call Today at 8:30 a.m. ET - Virios Therapeutics, Inc. (NASDAQ:VIRI), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat chronic diseases including fibromyalgia, today announced financial results for the fourth quarter and full year ended December 31, 2021. Key Highlights Phase 2b FORTRESS fibromyalgia study top line results on track for Q3 2022 Chronic toxicology studies, required for IMC-1 Phase 3 studies, are prog

Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat chronic diseases, including fibromyalgia, announced today that its fourth quarter and full year 2021 financial results will be reported on Thursday, March 17, 2022 before the open of the financial markets. Management will also host a webcast and conference call on March 17, 2022 at 8:30 a.m. ET to discuss the results and provide a corporate update. The live and archived webcast of the call may be accessed on the Virios Therapeutics website under the Investors section: Events and Presentations. The live call can also be accessed by dialing 888-506-0062

ORLANDO, FL / ACCESSWIRE / January 26, 2022 / RedChip Companies, Inc., an international investor relations, media, and research firm focused on microcap and small-cap companies, is pleased to announce its partnership with Benzinga to host an exclusive series of CEO interviews on January 28, beginning at 9:15 a.m. ET.The RedChip-Benzinga All Access event will feature interviews with senior executives from eight small-cap companies. Thousands of investors are expected to participate."We are excited to partner with Benzinga, a true leader in financial news media, for this exclusive event," commented Dave Gentry, CEO of RedChip Companies. "Benzinga attracts more than 25 million readers a month a

Over 200 patients Enrolled in Fibromyalgia Phase 2b Trial Filed Investigational New Drug Application with FDA to Assess IMC-1 Potential to Treat Irritable Bowel Syndrome Cash Position Supports Operations into Q1 2023 Management to Host Webcast and Conference Call at 8:30 a.m. EST November 11, 2021 Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, reported today financial results for the third quarter ended September 30, 2021 and provided a corporate update at 8:30 a.m. EST. "We are pleased to have enrolled over 200 patients into our landm

Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat chronic pain and fatigue related diseases, announced today that its third quarter 2021 financial results will be reported on Thursday, November 11, 2021 before the open of the financial markets. Management will also host a webcast and conference call on November 11, 2021 at 8:30 a.m. ET to discuss the results and provide a corporate update. The live and archived webcast of the call may be accessed on the Virios Therapeutics website under the Investors section: Events and Presentations. The live call can also be accessed by dialing 888-506-0062 (domesti

Virios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, today reported financial results for the second quarter ended June 30, 2021 and provided a corporate update. "Our landmark Phase 2b fibromyalgia clinical trial, referred to as FORTRESS, has rapidly progressed and patients are being enrolled at more than 40 clinical trial sites, keeping us on track to announce top line results in mid-2022," stated Greg Duncan, Chairman and Chief Executive Officer. "There is increasing recognition in the scientific community of the potential role of activated viruses triggering a wide range of

Virios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, announced today that its second quarter 2021 financial results will be reported on Thursday, August 12, 2021 before the open of the financial markets. Management will also host a webcast and conference call on August 12, 2021 at 8:30 a.m. ET to discuss the results and provide a corporate update. The live and archived webcast of the call may be accessed on the Virios Therapeutics website under the Investors section: Events and Presentations. The live call can also be accessed by dialing (844) 602-0380 (domestic) or (862) 298-